Summary
Pfizer Inc. filed an 8-K report on January 19, 2006, to announce its financial results for the fourth quarter of 2005. The report primarily references a press release issued on the same date, which contains the detailed financial outcomes for the period. Investors should refer to this press release, incorporated as Exhibit 99, for specific figures regarding revenue, earnings, and any forward-looking statements or guidance provided by the company. This filing serves as the official disclosure mechanism for Pfizer's Q4 2005 performance. While the 8-K itself is brief, its significance lies in directing stakeholders to the comprehensive financial information released concurrently. Key details for investors would likely include comparisons to previous periods, commentary on segment performance, and any material developments impacting the company's financial condition.
Key Highlights
- 1Pfizer Inc. announced its fourth quarter 2005 financial results via an 8-K filing on January 19, 2006.
- 2The 8-K filing incorporates by reference a press release dated January 19, 2006, containing the detailed financial results.
- 3Investors are directed to Exhibit 99 (the press release) for comprehensive financial data and commentary.
- 4The filing confirms the period covered is the fourth quarter of 2005.
- 5No other material events or disclosures beyond the financial results announcement were reported in this 8-K.
- 6The report was signed by Margaret M. Foran, Senior Vice President-Corporate Governance, Associate General Counsel and Secretary.